Augmedix, Inc. Common Stock
AUGX
AUGX was delisted on the 1st of October, 2024.
29 hedge funds and large institutions have $44.4M invested in Augmedix, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 2 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
29% more capital invested
Capital invested by funds: $34.4M → $44.4M (+$10M)
0% more funds holding
Funds holding: 29 → 29 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$2.05M |
| 2 |
CPA
Cowen Prime Advisors
New York
|
+$1.14M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
+$573K |
| 4 |
SC
Samjo Capital
New York
|
+$147K |
| 5 |
MAG
Millrace Asset Group
Berwyn,
Pennsylvania
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$71.1K |
| 2 |
William Blair & Company
Chicago,
Illinois
|
-$39.9K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.48K |
| 4 |
TCM
TD Capital Management
Memphis,
Tennessee
|
-$2.35K |
| 5 |
BTWM
Baker Tilly Wealth Management
Madison,
Wisconsin
|
-$1.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $10.7K | -$687 | -421 | -6% |
|
27
Wells Fargo
San Francisco,
California
| $2.06K | +$5 | +3 | +0.3% |
|
28
Morgan Stanley
New York
| $1.74K | – | – | – |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| – | -$4.48K | -2,745 | -96% |
|
|
TCM
30
TD Capital Management
Memphis,
Tennessee
| – | -$2.35K | -1,505 | Closed |
|
31
Bank of America
Charlotte,
North Carolina
| – | -$46 | -30 | Closed |
|
AUGX Hedge Fund Activity: Q1 2023 in Review
29 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Augmedix, Inc. Common Stock (AUGX) for Q1 2023, worth a combined $44.4M — up 29% from $34.4M a quarter earlier.
Fund positioning in AUGX was balanced in Q1 2023: 2 funds opened new positions, 2 closed out, 12 added to existing stakes and 7 trimmed.
The largest buyer was Russell Investments Group, adding an estimated $2.05M. The largest seller was Perkins Capital Management, cutting an estimated $71.1K.
- 29 institutional investors held Augmedix, Inc. Common Stock (AUGX) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $44.4M of Augmedix, Inc. Common Stock stock for Q1 2023, up 29% quarter-over-quarter.
- 2 funds opened new Augmedix, Inc. Common Stock positions in Q1 2023 and 2 closed out, a net change of 0 holders.
- The largest Augmedix, Inc. Common Stock buyer in Q1 2023 was Russell Investments Group, an estimated $2.05M added.
- The largest Augmedix, Inc. Common Stock seller in Q1 2023 was Perkins Capital Management, an estimated $71.1K sold.
Based on aggregated 13F filings for Q1 2023.